 The Deal Pipeline | Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b ... MarketWatch (press release) AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac surgery in patients at increased risk and has further potential in adjacent indications. AP214 is a hormone analogue that targets both systemic inflammation and ... Abbott hits the sweet spot, pays $110M cash for PhIIb drug Abbott Buys AP214 Hormone From Action Pharma For $110 Million Abbott buys potential kidney treatment for $110M |
